ascendis pharma glp-1 receptor agonist weight management diabetes treatments Novo inks deal to develop long-acting GLP-1, other metabolic drugs Understanding GLP-1 receptor agonists and
Description
2023;12(18) doi: 10.3390/jcm12185915
You deserve a plan that works for your body and your life
Depending on patient-specific factors and associated risks, anesthesia providers could consider treating these patients as if they have a full stomach
A focused gastrointestinal review should ask about nausea, vomiting, abdominal distension, reflux, early satiety, constipation, postprandial fullness, and prior gastroparesis
Additional support was provided by American Diabetes Association Basic Research Awards 7-12-BS-077 (G.G.H) and 1-12-BS-109 (C.A.L.)
16(9): e68390
